FDA clears the first GLP‑1 pill
The FDA has approved oral semaglutide as the first GLP‑1 pill for weight loss, broadening how the class can be taken beyond injectables (ajmc.com). Nutritionists warn that people on GLP‑1s still need to prioritize protein, fiber and micronutrients because appetite suppression can make getting enough nutrients harder (businessinsider.com).
The Food and Drug Administration has cleared Wegovy tablets, making semaglutide the first pill in the glucagon-like peptide-1 class approved for chronic weight management in adults. (accessdata.fda.gov) Wegovy tablets are approved with a reduced-calorie diet and increased physical activity for adults with obesity, or adults with overweight plus at least one weight-related condition. The label also says the tablet form is approved to reduce major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. (accessdata.fda.gov) Glucagon-like peptide-1 drugs copy a gut hormone that helps regulate appetite and blood sugar. Wegovy’s prescribing information says the medicine also slows stomach emptying, which is one reason people tend to feel full sooner. (who.int) (wegovy.com) In the 64-week trial cited by Novo Nordisk, 307 adults without diabetes were assigned to a once-daily Wegovy pill or placebo, alongside diet and exercise. Adults taking the pill lost an average of 14% of body weight, versus 2.4% for placebo. (wegovy.com) The same study says 76% of adults on the pill lost at least 5% of body weight, 60% lost at least 10%, and 47% lost at least 15%. About 28% lost 20% or more. (wegovy.com) The approval adds a second way to take semaglutide for obesity after weekly injections. Novo Nordisk’s product pages list Wegovy injection at 2.4 milligrams once a week and Wegovy tablets at 25 milligrams once a day. (accessdata.fda.gov) (novomedlink.com) The pill comes with the same broad safety frame patients already see with semaglutide products. The label carries a boxed warning about thyroid C-cell tumors seen in rodents and says the drug should not be used in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) Doctors and dietitians say the new format does not remove the nutrition problem created by appetite suppression. A 2025 joint clinical advisory from four medical and nutrition groups says people on glucagon-like peptide-1 drugs can struggle to get enough protein because lower appetite and food aversions make adequate intake harder. (ajcn.nutrition.org) (nutrition.org) That advisory says care on these drugs should also focus on gastrointestinal side effects, nutrient deficiencies from calorie reduction, and preserving muscle and bone mass with diet and resistance training. The pill changes the route of delivery, but the label still says it is meant to be used with diet and physical activity, not instead of them. (pmc.ncbi.nlm.nih.gov) (accessdata.fda.gov)
